FTC loses appeal against Endo-Impax agreement
The Federal Trade Commission failed to demonstrate that a settlement between Endo Pharmaceuticals and Impax Laboratories caused anticompetitive harm beyond what US patent law allows, an appellate panel has said.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10